Metuchen Pharmaceuticals is a privately-held healthcare company founded by pharmaceutical industry veterans. The company identifies, acquires, develops and commercializes products that have significant clinical advantages and patent protection. Metuchen has a full range of commercial capabilities including sales, marketing regulatory and medical affairs, finance, trade relations, pharmacovigilance, managed care customer management, manufacturing and distribution. All products are manufactured by well-known third party producers. The company recently acquired the rights to Stendra® (avanafil tablets), a novel PDE-5 inhibitor for the treatment of erectile dysfunction (ED). Metuchen is currently offering partners the opportunity to license Stendra in Canada, India and South America.